EVAX Fundamental Analysis - EVAXION A/S

Fundamental Rating

Taking everything into account, EVAX scores 2 out of 10 in our fundamental rating. EVAX was compared to 530 industry peers in the Biotechnology industry. The financial health of EVAX is average, but there are quite some concerns on its profitability. While showing a medium growth rate, EVAX is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

EVAX had negative earnings in the past year.

In the past year EVAX has reported a negative cash flow from operations.

In the past 5 years EVAX always reported negative net income.

In the past 5 years EVAX always reported negative operating cash flow.

1.2 Ratios

With a Return On Assets value of -53.35%, EVAX perfoms like the industry average, outperforming 46.60% of the companies in the same industry.

Looking at the Return On Equity, with a value of -192.35%, EVAX is doing worse than 66.98% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-53.35%
ROE	-192.35%
ROIC	N/A

ROA(3y)-120.5%

ROA(5y)-109.62%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for EVAX so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

EVAX does not have a ROIC to compare to the WACC, probably because it is not profitable.

EVAX has more shares outstanding than it did 1 year ago.

The number of shares outstanding for EVAX has been reduced compared to 5 years ago.

Compared to 1 year ago, EVAX has an improved debt to assets ratio.

2.2 Solvency

EVAX has an Altman-Z score of 0.01. This is a bad value and indicates that EVAX is not financially healthy and even has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of 0.01, EVAX is in the better half of the industry, outperforming 60.19% of the companies in the same industry.

A Debt/Equity ratio of 1.73 is on the high side and indicates that EVAX has dependencies on debt financing.

The Debt to Equity ratio of EVAX (1.73) is worse than 77.36% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	1.73
Debt/FCF	N/A
Altman-Z	0.01

ROIC/WACCN/A

WACC5.71%

2.3 Liquidity

A Current Ratio of 3.42 indicates that EVAX has no problem at all paying its short term obligations.

With a Current ratio value of 3.42, EVAX perfoms like the industry average, outperforming 40.94% of the companies in the same industry.

EVAX has a Quick Ratio of 3.42. This indicates that EVAX is financially healthy and has no problem in meeting its short term obligations.

With a Quick ratio value of 3.42, EVAX perfoms like the industry average, outperforming 43.21% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	3.42
Quick Ratio	3.42

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

EVAX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 45.07%, which is quite impressive.

EVAX shows a strong growth in Revenue. In the last year, the Revenue has grown by 132.20%.

EPS 1Y (TTM)45.07%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%105%

Revenue 1Y (TTM)132.2%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%148.33%

3.2 Future

Based on estimates for the next years, EVAX will show a quite strong growth in Earnings Per Share. The EPS will grow by 15.29% on average per year.

The Revenue is expected to grow by 40.90% on average over the next years. This is a very strong growth

EPS Next Y85.61%

EPS Next 2Y32.17%

EPS Next 3Y25.84%

EPS Next 5Y15.29%

Revenue Next Year14.66%

Revenue Next 2Y-56.29%

Revenue Next 3Y-25.99%

Revenue Next 5Y40.9%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EVAX. In the last year negative earnings were reported.

Also next year EVAX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as EVAX's earnings are expected to grow with 25.84% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y32.17%

EPS Next 3Y25.84%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for EVAX!.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

EVAXION A/S

NASDAQ:EVAX (1/8/2026, 4:30:02 PM)

5.11

-0.28 (-5.19%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-06 2025-11-06/bmo

Earnings (Next)03-05 2026-03-05/amc

Inst Owners1.48%

Inst Owner Change0%

Ins Owners0.68%

Ins Owner ChangeN/A

Market Cap40.49M

Revenue(TTM)7.65M

Net Income(TTM)-11.98M

Analysts82.22

Price Target12.58 (146.18%)

Short Float %1.94%

Short Ratio0.62

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)60.81%

Min EPS beat(2)24.59%

Max EPS beat(2)97.03%

EPS beat(4)4

Avg EPS beat(4)54.87%

Min EPS beat(4)11.56%

Max EPS beat(4)97.03%

EPS beat(8)7

Avg EPS beat(8)54.84%

EPS beat(12)10

Avg EPS beat(12)37.39%

EPS beat(16)13

Avg EPS beat(16)31.2%

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)12.12%

EPS NQ rev (1m)0%

EPS NQ rev (3m)159.7%

EPS NY rev (1m)40.15%

EPS NY rev (3m)85.98%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)491.19%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	12.75
P/FCF	N/A
P/OCF	N/A
P/B	6.5
P/tB	6.5
EV/EBITDA	N/A

EPS(TTM)-4.01

EYN/A

EPS(NY)-0.71

Fwd EYN/A

FCF(TTM)-1.47

FCFYN/A

OCF(TTM)-1.47

OCFYN/A

SpS0.4

BVpS0.79

TBVpS0.79

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-53.35%
ROE	-192.35%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-120.5%

ROA(5y)-109.62%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score6

Asset Turnover0.14

Health

		Industry Rank	Sector Rank
Debt/Equity	1.73
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	3.42
Quick Ratio	3.42
Altman-Z	0.01

F-Score6

WACC5.71%

ROIC/WACCN/A

Cap/Depr(3y)21.76%

Cap/Depr(5y)127.17%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)45.07%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%105%

EPS Next Y85.61%

EPS Next 2Y32.17%

EPS Next 3Y25.84%

EPS Next 5Y15.29%

Revenue 1Y (TTM)132.2%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%148.33%

Revenue Next Year14.66%

Revenue Next 2Y-56.29%

Revenue Next 3Y-25.99%

Revenue Next 5Y40.9%

EBIT growth 1Y26.93%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year61.67%

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y50.81%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y50.7%

OCF growth 3YN/A

OCF growth 5YN/A

EVAXION A/S / EVAX FAQ

Can you provide the ChartMill fundamental rating for EVAXION A/S?

ChartMill assigns a fundamental rating of 2 / 10 to EVAX.

Can you provide the valuation status for EVAXION A/S?

ChartMill assigns a valuation rating of 1 / 10 to EVAXION A/S (EVAX). This can be considered as Overvalued.

How profitable is EVAXION A/S (EVAX) stock?

EVAXION A/S (EVAX) has a profitability rating of 0 / 10.

What is the expected EPS growth for EVAXION A/S (EVAX) stock?

The Earnings per Share (EPS) of EVAXION A/S (EVAX) is expected to grow by 85.61% in the next year.

EVAXION A/S (EVAX) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

EVAXION A/S / EVAX FAQ

Can you provide the ChartMill fundamental rating for EVAXION A/S?

Can you provide the valuation status for EVAXION A/S?

How profitable is EVAXION A/S (EVAX) stock?

What is the expected EPS growth for EVAXION A/S (EVAX) stock?